The Effects of Filgrastim on Prognosis of Patients with acute Ischemic Stroke

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20141209020258N63

Enrollment

Registered

2018-01-22

Start date

2016-06-19

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute Ischemic Stroke. Cerebral infarction, unspecified

Interventions

Intervention 1: Intervention group: We treat patients(42 person) by 150 milligram in 24 hours Filgrastim in 3 ?days in intervention group. Intervention 2: Control group: We treat patients(42 person)

Treatment - Drugs

Intervention group: We treat patients(42 person) by 150 milligram in 24 hours Filgrastim in 3 ?days in intervention group.

Control group: We treat patients(42 person) 150 milligram in 24 hours normal salin in control ?group.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 18 years and more Patients with acute ischemic stroke

Exclusion criteria

Exclusion criteria: Drinking alcohol and addict Incidence of side effects or the sensitivity of the drug History of blood pressure, diabetes, embolism and DVT Death of the patient 72 hours after entering the emergency room

Design outcomes

Primary

Measure	Time frame
Hemoglobin. Timepoint: Before and during treatment and 4 weeks after treatment. Method of measurement: blood test.;Power of the paraplegic organ. Timepoint: Before and during treatment and 4 weeks after treatment. Method of measurement: Physical examination.;Awareness status. Timepoint: Before and during treatment and 4 weeks after treatment. Method of measurement: Glasgow Coma Scale.;Motion status. Timepoint: Before and during treatment and 4 weeks after treatment. Method of measurement: Physical examination.;Hematocrit. Timepoint: Before and during treatment and 4 weeks after treatment. Method of measurement: blood test.	—

Measure

Time frame

Hemoglobin. Timepoint: Before and during treatment and 4 weeks after treatment. Method of measurement: blood test.;Power of the paraplegic organ. Timepoint: Before and during treatment and 4 weeks after treatment. Method of measurement: Physical examination.;Awareness status. Timepoint: Before and during treatment and 4 weeks after treatment. Method of measurement: Glasgow Coma Scale.;Motion status. Timepoint: Before and during treatment and 4 weeks after treatment. Method of measurement: Physical examination.;Hematocrit. Timepoint: Before and during treatment and 4 weeks after treatment. Method of measurement: blood test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Morteza Gharibi

Arak University of Medical Sciences

gharibi@arakmu.ac.ir+98 86 3222 2003

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026